Sarepta shares fall on potential regulatory delay for experimental Duchenne drug

Shares of Sarepta Therapeutics Inc. SRPT, +0.09% were down 0.7% in premarket trading on Thursday, the day after the company said it had submitted a written response to the Food and Drug Administration for its investigational Duchenne muscular dystrophy treatment.